Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma

Autor Arnulf, Bertrand, Pylypenko, Halyna, Grosicki, Sebastian, Karamanesht, Ievgenii, Leleu, Xavier, van de Velde, Helgi, Feng, Huaibao, Cakana, Andrew, Deraedt, William, Moreau, Philippe
Vydáno 2012

A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia

Autor Kipps, Thomas J., Eradat, Herbert, Grosicki, Sebastian, Catalano, John, Cosolo, Walter, Dyagil, Iryna S., Yalamanchili, Sreeni, Chai, Akiko, Sahasranaman, Srikumar, Punnoose, Elizabeth, Hurst, Deborah, Pylypenko, Halyna
Vydáno v Leuk Lymphoma (2015)

Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study

Autor Moreau, Philippe, Pylypenko, Halyna, Grosicki, Sebastian, Karamanesht, Ievgenii, Leleu, Xavier, Rekhtman, Grigoriy, Masliak, Zvenyslava, Robak, Pawel, Esseltine, Dixie-Lee, Feng, Huaibao, Deraedt, William, van de Velde, Helgi, Arnulf, Bertrand
Vydáno v Haematologica (2015)

Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study

Autor Verhoef, Gregor, Robak, Tadeusz, Huang, Huiqiang, Pylypenko, Halyna, Siritanaratkul, Noppadol, Pereira, Juliana, Drach, Johannes, Mayer, Jiri, Okamoto, Rumiko, Pei, Lixia, Rooney, Brendan, Cakana, Andrew, van de Velde, Helgi, Cavalli, Franco
Vydáno v Haematologica (2017)

Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups

Autor Gisslinger, Heinz, Klade, Christoph, Georgiev, Pencho, Krochmalczyk, Dorota, Gercheva-Kyuchukova, Liana, Egyed, Miklos, Rossiev, Viktor, Dulicek, Petr, Illes, Arpad, Pylypenko, Halyna, Sivcheva, Lylia, Mayer, Jiri, Yablokova, Vera, Krejcy, Kurt, Hasselbalch, Hans C., Kralovics, Robert, Kiladjian, Jean-Jacques
Vydáno v Hemasphere (2020)

Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma

Autor Mateos, Maria V., Gavriatopoulou, Maria, Facon, Thierry, Auner, Holger W., Leleu, Xavier, Hájek, Roman, Dimopoulos, Meletios A., Delimpasi, Sosana, Simonova, Maryana, Špička, Ivan, Pour, Ludĕk, Kriachok, Iryna, Pylypenko, Halyna, Doronin, Vadim, Usenko, Ganna, Benjamin, Reuben, Dolai, Tuphan K., Sinha, Dinesh K., Venner, Christopher P., Garg, Mamta, Stevens, Don A., Quach, Hang, Jagannath, Sundar, Moreau, Philippe, Levy, Moshe, Badros, Ashraf Z., Anderson, Larry D., Bahlis, Nizar J., Cavo, Michele, Chai, Yi, Jeha, Jacqueline, Arazy, Melina, Shah, Jatin, Shacham, Sharon, Kauffman, Michael G., Richardson, Paul G., Grosicki, Sebastian
Vydáno v J Hematol Oncol (2021)